ALPHA-V-BETA-8 INTEGRIN INHIBITORS AND USES THEREOF
The disclosure relates to compounds of formula (A) and formula (I), e.g.: (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, L1, L2, L3, Y, and Q are as described herein. Compounds of formula (A) and formula (I) and pharmaceutical compositions thereof are inhibitors of at lea...
Gespeichert in:
Hauptverfasser: | , , , , , |
---|---|
Format: | Patent |
Sprache: | eng ; fre |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | |
container_start_page | |
container_title | |
container_volume | |
creator | MUNOZ, Manuel Angel MACHAJEWSKI, Timothy D LEFTHERIS, Katerina MONTELEONE, Dennis HOM, Timothy F FINKELSTEIN, Darren |
description | The disclosure relates to compounds of formula (A) and formula (I), e.g.: (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, L1, L2, L3, Y, and Q are as described herein. Compounds of formula (A) and formula (I) and pharmaceutical compositions thereof are inhibitors of at least one or more of avPs, avPi, and avPe integrins. Also disclosed are methods for treating fibrosis such as nonalcoholic steatohepatitis (NASH), idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP), and cancer comprising administration of the compounds and pharmaceutical compositions thereof.
La divulgation concerne des composés de formule (A) et de formule (I), par exemple : (I) ou un sel pharmaceutiquement acceptable de celui-ci, où R1, R2, R3, R4, L1, L2, L3, Y, et Q sont tels que décrits dans la description. La divulgation concerne des composés de formule (A) et de formule (I) et des compositions pharmaceutiques de ceux-ci qui sont des inhibiteurs d'au moins une ou plusieurs des intégrines AVP, avPi et avPe. La divulgation concerne également des méthodes de traitement de la fibrose telle que la stéatohépatite non alcoolique (NASH), la fibrose pulmonaire idiopathique (IPF) et la pneumonie interstitielle non spécifique (NSIP), et le cancer comprenant l'administration des composés et des compositions pharmaceutiques de ceux-ci. |
format | Patent |
fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_WO2024145245A3</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>WO2024145245A3</sourcerecordid><originalsourceid>FETCH-epo_espacenet_WO2024145245A33</originalsourceid><addsrcrecordid>eNrjZDB29AnwcNQN03VyDXHUtVDw9AtxdQ_y9AMyPDydPEP8g4IVHP1cFEKDXYMVQjxcg1z93XgYWNMSc4pTeaE0N4Oym2uIs4duakF-fGpxQWJyal5qSXy4v5GBkYmhiamRiamjsTFxqgAVHCe6</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>ALPHA-V-BETA-8 INTEGRIN INHIBITORS AND USES THEREOF</title><source>esp@cenet</source><creator>MUNOZ, Manuel Angel ; MACHAJEWSKI, Timothy D ; LEFTHERIS, Katerina ; MONTELEONE, Dennis ; HOM, Timothy F ; FINKELSTEIN, Darren</creator><creatorcontrib>MUNOZ, Manuel Angel ; MACHAJEWSKI, Timothy D ; LEFTHERIS, Katerina ; MONTELEONE, Dennis ; HOM, Timothy F ; FINKELSTEIN, Darren</creatorcontrib><description>The disclosure relates to compounds of formula (A) and formula (I), e.g.: (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, L1, L2, L3, Y, and Q are as described herein. Compounds of formula (A) and formula (I) and pharmaceutical compositions thereof are inhibitors of at least one or more of avPs, avPi, and avPe integrins. Also disclosed are methods for treating fibrosis such as nonalcoholic steatohepatitis (NASH), idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP), and cancer comprising administration of the compounds and pharmaceutical compositions thereof.
La divulgation concerne des composés de formule (A) et de formule (I), par exemple : (I) ou un sel pharmaceutiquement acceptable de celui-ci, où R1, R2, R3, R4, L1, L2, L3, Y, et Q sont tels que décrits dans la description. La divulgation concerne des composés de formule (A) et de formule (I) et des compositions pharmaceutiques de ceux-ci qui sont des inhibiteurs d'au moins une ou plusieurs des intégrines AVP, avPi et avPe. La divulgation concerne également des méthodes de traitement de la fibrose telle que la stéatohépatite non alcoolique (NASH), la fibrose pulmonaire idiopathique (IPF) et la pneumonie interstitielle non spécifique (NSIP), et le cancer comprenant l'administration des composés et des compositions pharmaceutiques de ceux-ci.</description><language>eng ; fre</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2024</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20240802&DB=EPODOC&CC=WO&NR=2024145245A3$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,309,781,886,25568,76551</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20240802&DB=EPODOC&CC=WO&NR=2024145245A3$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>MUNOZ, Manuel Angel</creatorcontrib><creatorcontrib>MACHAJEWSKI, Timothy D</creatorcontrib><creatorcontrib>LEFTHERIS, Katerina</creatorcontrib><creatorcontrib>MONTELEONE, Dennis</creatorcontrib><creatorcontrib>HOM, Timothy F</creatorcontrib><creatorcontrib>FINKELSTEIN, Darren</creatorcontrib><title>ALPHA-V-BETA-8 INTEGRIN INHIBITORS AND USES THEREOF</title><description>The disclosure relates to compounds of formula (A) and formula (I), e.g.: (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, L1, L2, L3, Y, and Q are as described herein. Compounds of formula (A) and formula (I) and pharmaceutical compositions thereof are inhibitors of at least one or more of avPs, avPi, and avPe integrins. Also disclosed are methods for treating fibrosis such as nonalcoholic steatohepatitis (NASH), idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP), and cancer comprising administration of the compounds and pharmaceutical compositions thereof.
La divulgation concerne des composés de formule (A) et de formule (I), par exemple : (I) ou un sel pharmaceutiquement acceptable de celui-ci, où R1, R2, R3, R4, L1, L2, L3, Y, et Q sont tels que décrits dans la description. La divulgation concerne des composés de formule (A) et de formule (I) et des compositions pharmaceutiques de ceux-ci qui sont des inhibiteurs d'au moins une ou plusieurs des intégrines AVP, avPi et avPe. La divulgation concerne également des méthodes de traitement de la fibrose telle que la stéatohépatite non alcoolique (NASH), la fibrose pulmonaire idiopathique (IPF) et la pneumonie interstitielle non spécifique (NSIP), et le cancer comprenant l'administration des composés et des compositions pharmaceutiques de ceux-ci.</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2024</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZDB29AnwcNQN03VyDXHUtVDw9AtxdQ_y9AMyPDydPEP8g4IVHP1cFEKDXYMVQjxcg1z93XgYWNMSc4pTeaE0N4Oym2uIs4duakF-fGpxQWJyal5qSXy4v5GBkYmhiamRiamjsTFxqgAVHCe6</recordid><startdate>20240802</startdate><enddate>20240802</enddate><creator>MUNOZ, Manuel Angel</creator><creator>MACHAJEWSKI, Timothy D</creator><creator>LEFTHERIS, Katerina</creator><creator>MONTELEONE, Dennis</creator><creator>HOM, Timothy F</creator><creator>FINKELSTEIN, Darren</creator><scope>EVB</scope></search><sort><creationdate>20240802</creationdate><title>ALPHA-V-BETA-8 INTEGRIN INHIBITORS AND USES THEREOF</title><author>MUNOZ, Manuel Angel ; MACHAJEWSKI, Timothy D ; LEFTHERIS, Katerina ; MONTELEONE, Dennis ; HOM, Timothy F ; FINKELSTEIN, Darren</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_WO2024145245A33</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2024</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>MUNOZ, Manuel Angel</creatorcontrib><creatorcontrib>MACHAJEWSKI, Timothy D</creatorcontrib><creatorcontrib>LEFTHERIS, Katerina</creatorcontrib><creatorcontrib>MONTELEONE, Dennis</creatorcontrib><creatorcontrib>HOM, Timothy F</creatorcontrib><creatorcontrib>FINKELSTEIN, Darren</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>MUNOZ, Manuel Angel</au><au>MACHAJEWSKI, Timothy D</au><au>LEFTHERIS, Katerina</au><au>MONTELEONE, Dennis</au><au>HOM, Timothy F</au><au>FINKELSTEIN, Darren</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>ALPHA-V-BETA-8 INTEGRIN INHIBITORS AND USES THEREOF</title><date>2024-08-02</date><risdate>2024</risdate><abstract>The disclosure relates to compounds of formula (A) and formula (I), e.g.: (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, L1, L2, L3, Y, and Q are as described herein. Compounds of formula (A) and formula (I) and pharmaceutical compositions thereof are inhibitors of at least one or more of avPs, avPi, and avPe integrins. Also disclosed are methods for treating fibrosis such as nonalcoholic steatohepatitis (NASH), idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP), and cancer comprising administration of the compounds and pharmaceutical compositions thereof.
La divulgation concerne des composés de formule (A) et de formule (I), par exemple : (I) ou un sel pharmaceutiquement acceptable de celui-ci, où R1, R2, R3, R4, L1, L2, L3, Y, et Q sont tels que décrits dans la description. La divulgation concerne des composés de formule (A) et de formule (I) et des compositions pharmaceutiques de ceux-ci qui sont des inhibiteurs d'au moins une ou plusieurs des intégrines AVP, avPi et avPe. La divulgation concerne également des méthodes de traitement de la fibrose telle que la stéatohépatite non alcoolique (NASH), la fibrose pulmonaire idiopathique (IPF) et la pneumonie interstitielle non spécifique (NSIP), et le cancer comprenant l'administration des composés et des compositions pharmaceutiques de ceux-ci.</abstract><oa>free_for_read</oa></addata></record> |
fulltext | fulltext_linktorsrc |
identifier | |
ispartof | |
issn | |
language | eng ; fre |
recordid | cdi_epo_espacenet_WO2024145245A3 |
source | esp@cenet |
subjects | CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
title | ALPHA-V-BETA-8 INTEGRIN INHIBITORS AND USES THEREOF |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-16T16%3A48%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=MUNOZ,%20Manuel%20Angel&rft.date=2024-08-02&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EWO2024145245A3%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |